2 completed, 1 active not recruiting, 1 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow relacorilant: new trials by email Literature Review of relacorilant trials Research Report on relacorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2 - Ovarian Neoplasm, Fallopian Tube Neoplasms | Phase 3 | Active not recruiting | Corcept Therapeutics | 381 | 2022-06-29 | 2026-09-25 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Relacorilant, Placebo - Hypercortisolism | Phase 3 | Completed | Corcept Therapeutics | 137 | 2020-07-27 | 2025-09-04 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Corcept Therapeutics | 43 | 2020-06-30 | 2023-11-18 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
ACTH Syndrome, Ectopic (2) · Cushing Syndrome (2) · Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1) · Pituitary ACTH Hypersecretion (1)
United States (4) · Israel (3) · Italy (3) · Poland (3) · Spain (3) · Austria (2) · Bulgaria (2) · Canada (2) · Germany (2) · Romania (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · France (1)
Andreas Moraitis, MD (2) · Adrian Jubb, MBChB, PhD, FRCPath (1) · William Guyer, PharmD (1)
PMID 35058882, PMID 37364223, PMID 39032926, PMID 40473448, PMID 41730814, PMID 41974149